Search

Your search keyword '"Vinuesa D"' showing total 78 results

Search Constraints

Start Over You searched for: Author "Vinuesa D" Remove constraint Author: "Vinuesa D"
78 results on '"Vinuesa D"'

Search Results

1. COHORTE EN-DALBACEN 2.0: DALBAVANCINA COMO TRATAMIENTO ANTIBIÓTICO DE CONSOLIDACIÓN DE EI POR COCOS GRAM POSITIVOS

3. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

4. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

6. DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

7. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

8. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

10. Mild profile improvement of immune biomarkers in HIV/HCV-coinfected patients who removed hepatitis C after HCV treatment: A prospective study

11. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57).

12. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015

13. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice

14. Effect of the type of surgical indication on mortality in patients with infective endocarditis who are rejected for surgical intervention

15. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR

20. 18. Causas y pronóstico de la reintervención quirúrgica precoz en endocarditis infecciosa izquierda

21. All-cause mortality in the cohorts of the Spanish AIDS Rearch Network (RIS) compared with the general population: 1997-2010

22. All-cause mortality in the cohorts of the Spanish AIDS Rearch Network (RIS) compared with the general population: 1997-2010

28. Clinical Factors Associated with Reinfection versus Relapse in Infective Endocarditis: Prospective Cohort Study

29. Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain

30. All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010

31. Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.

32. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.

33. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.

34. Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial.

35. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.

36. Ampicillin Plus Ceftriaxone Combined Therapy for Enterococcus faecalis Infective Endocarditis in OPAT.

37. Infective endocarditis in patients with heart transplantation.

38. Clinical Factors Associated with Reinfection versus Relapse in Infective Endocarditis: Prospective Cohort Study.

39. Increased Frequencies of Myeloid-Derived Suppressor Cells Precede Immunodiscordance in HIV-Infected Subjects.

41. Clinical and prognostic differences between methicillin-resistant and methicillin-susceptible Staphylococcus aureus infective endocarditis.

42. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.

43. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice.

44. Clinical predictors of candidemia in medical non-neutropenic, non-ICU patients. The CaMed score.

45. High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach.

46. Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain.

47. Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure.

48. [Study of human immunodeficiency virus transmission chains in Andalusia: analysis from baseline antiretroviral resistance sequences].

49. Nebulized medication is not associated with nosocomial infections. A pilot study.

50. Protease inhibitor monotherapy is not associated with increased viral replication in lymph nodes.

Catalog

Books, media, physical & digital resources